Idiopathic Nephrotic Syndrome Clinical Trial
— NEPHROVIR-2Official title:
Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome
Verified date | March 2017 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary purpose of the study is to identify the factors of steroid dependency in childhood idiopathic nephrotic syndrome. The steroid dependency is defined by a relapse of nephrotic syndrome within the 3 weeks that follow the withdrawal of steroid therapy after the first manifestation. Different clinical and biological factors will be analyzed: age of first manifestation, delay of remission, ethnicity, and preceding viral infection, geolocalization in the Parisian area, genoprevalence of herpes viruses and polymorphisms in the genes involved in the response to steroid therapy.
Status | Completed |
Enrollment | 351 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 16 Years |
Eligibility |
Inclusion Criteria: - children below 16 years - first manifestation of nephrotic syndrome - steroid sensitivity according to the recommendations of the french "pediatric society nephrology" Exclusion Criteria: - patients who don't stay in Paris during the study |
Country | Name | City | State |
---|---|---|---|
France | APHP Robert-Debré, Department of Pediatric Nephrology | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | define pharmacogenetic factors of steroid dependency | 28.5 months | ||
Secondary | parameters of the immune response against herpesvirus, specially the cellular production of interferon induced by specific viral peptides | 28.5 months | ||
Secondary | Dynamic of the epidemiology of idiopathic nephrotic syndrome in the Paris Area | Number of participants with idiopathic nephrotic syndrome in Paris Area to determinate if clusters cases exist. | 28.5 months | |
Secondary | Analysis of cortico-dependence factors | Comparison of polymorphisms of cortico-dependent patients with non- cortico-dependent patients | Day 1 | |
Secondary | Analysis of susceptibility factors that generate the appearance of the Idiopathic Nephrotic Syndrome | Comparison of polymorphisms of all patients suffering from the Idiopathic Nephrotic Syndrome, with general population | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01092962 -
Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children
|
Phase 3 | |
Recruiting |
NCT04075656 -
UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
|
N/A | |
Recruiting |
NCT02896270 -
Valproic Acid for Idiopathic Nephrotic Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT04034316 -
Reduce Immunosuppression With Atmp in NS ChildrEn
|
Phase 2 | |
Completed |
NCT00255398 -
Kidney Disease Biomarkers
|
||
Recruiting |
NCT04207580 -
A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
|
||
Completed |
NCT04494438 -
Rituximab for Idiopathic Nephrotic Syndrome
|
Phase 3 | |
Active, not recruiting |
NCT01346007 -
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
|
Phase 4 | |
Completed |
NCT04169776 -
Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome
|
N/A | |
Recruiting |
NCT03298698 -
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
|
Phase 3 | |
Recruiting |
NCT03949972 -
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
|